Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Pediatric Cardiology
S. Kristen Sexson Tejtel, MD, PhD, MPHPediatric Preventive Cardiology
TCHAPP ConferenceApril 4, 2019
Kawasaki Disease:What you need to know from the 2017 Guidelines
No disclosures to report
Page 1
xxx00.#####.ppt 4/10/19 10:37:31 AMPediatric Cardiology Pediatric
•History of KD/Epidemiology
•2017 Guidelines- Diagnosis –
• Classic cases • The challenges of diagnosis• Echocardiography in KD• Need for additional imaging
- Treatment• The future of initial KD therapy• IVIG resistance - Knowing when to retreat• Complex cases
• KDSS• KD with severe coronary artery aneurysms• Persistent features without fever
• Thromboprophylaxis in KD- Follow-up
• When to follow-up• Immunizations after IVIG for KD
Outline
Page 2
xxx00.#####.ppt 4/10/19 10:37:32 AMPediatric Cardiology Pediatric
•Ka·wa·sa·ki dis·ease - noun
•a disease of unknown cause, occurring primarily in young children and giving rise to a rash, glandular swelling, and sometimes damage to the heart.
What is Kawasaki Disease (KD)?
Page 3
xxx00.#####.ppt 4/10/19 10:37:33 AMPediatric Cardiology Pediatric
• Etiology: Infection? à Infectious Disease?
• Diagnosis/Treatmentà Pediatrics/Hospitalists?
• Pathophysiology: Vasculitis à Rheumatology?
• Consequence: Coronary Aneurysms à Cardiology?
Who “Owns” KD?
Page 4
xxx00.#####.ppt 4/10/19 10:37:33 AMPediatric Cardiology Pediatric
Kawasaki Disease (KD) History
Page 5
xxx00.#####.ppt 4/10/19 10:37:34 AMPediatric Cardiology Pediatric
•Annual US incidence ~25 per 100,000 children <5yrs old
•80-90% of cases occur in children <5yrs old•Peak 18-24 mo
•Rare beyond late childhood•Older children may experience delays in diagnosis
•Boys > Girls (1.5:1)
Epidemiology
Page 6
xxx00.#####.ppt 4/10/19 10:37:35 AMPediatric Cardiology Pediatric
•Japan: •10x increased risk with an affected sibling
•2x increased risk with a previously affected parent
Epidemiology
Page 7
xxx00.#####.ppt 4/10/19 10:37:36 AMPediatric Cardiology Pediatric
Pathophysiology
Page 8
xxx00.#####.ppt 4/10/19 10:37:37 AMPediatric Cardiology Pediatric
Complete KD
Page 9
xxx00.#####.ppt 4/10/19 10:37:37 AMPediatric Cardiology Pediatric
Page 10
xxx00.#####.ppt 4/10/19 10:37:38 AMPediatric Cardiology Pediatric
Page 11
xxx00.#####.ppt 4/10/19 10:37:39 AMPediatric Cardiology Pediatric
Page 12
xxx00.#####.ppt 4/10/19 10:37:39 AMPediatric Cardiology Pediatric
Page 13
xxx00.#####.ppt 4/10/19 10:37:40 AMPediatric Cardiology Pediatric
Page 14
xxx00.#####.ppt 4/10/19 10:37:41 AMPediatric Cardiology Pediatric
IRRITABILITY
Page 15
xxx00.#####.ppt 4/10/19 10:37:42 AMPediatric Cardiology Pediatric
•Systemic inflammation of medium-sized arteries and multiple organs
•Associated clinical findings:- liver (hepatitis), - lung (interstitial pneumonitis), -gastrointestinal tract (abdominal pain, vomiting, diarrhea, gallbladder hydrops), -meninges (aseptic meningitis, irritability),-heart (myocarditis, pericarditis, valvulitis), -urinary tract (pyuria), -pancreas (pancreatitis), - lymph nodes (lymphadenopathy).
KD Characteristics
Page 16
xxx00.#####.ppt 4/10/19 10:37:42 AMPediatric Cardiology Pediatric
•The signs are common
•There is no gold standard lab test
•The stakes are high
•A missed diagnosis may manifest years (or decades) later
•However, are we over-diagnosing?
The Challenges of Diagnosis
Page 17
xxx00.#####.ppt 4/10/19 10:37:43 AMPediatric Cardiology Pediatric
•How about incomplete KD?
The Challenges of Diagnosis
Page 18
xxx00.#####.ppt 4/10/19 10:37:44 AMPediatric Cardiology Pediatric
2017 Guideline
Page 19
xxx00.#####.ppt 4/10/19 10:37:45 AMPediatric Cardiology Pediatric
Echo in KD
Page 20
xxx00.#####.ppt 4/10/19 10:37:46 AMPediatric Cardiology Pediatric
•Any of 3 conditions are met: -Z score of LAD or RCA ≥2.5
-Coronary artery aneurysm
-≥3 other suggestive features:
•decreased left ventricular function
•mitral regurgitation
•pericardial effusion
•Z scores in the LAD or RCA of 2 to 2.5
2017 Guidelines –What Defines a Positive Echocardiogram?
Page 21
xxx00.#####.ppt 4/10/19 10:37:47 AMPediatric Cardiology Pediatric
•Summary:1. Echobrightness
2. Ectasia
3. Lack of distal tapering
4. Dilation
5. Aneurysm formation
6. Valve regurgitation
7. Aortic root involvement
8. Function
9. Pericardial Effusion
TCH KD Echo Read
Page 22
xxx00.#####.ppt 4/10/19 10:37:47 AMPediatric Cardiology Pediatric
•Z-Score Classification – Risk Level1. No involvement: Always <22. Dilation only: 2 to <2.5; or if initially <2, a decrease in Z
score during follow-up ≥1
3. Small aneurysm: ≥2.5 to <54. Medium aneurysm: ≥5 to <10, and absolute5. dimension <8 mm6. Large or giant aneurysm: ≥10, or absolute dimension ≥8
mm
Coronary Artery Involvement
Page 23
xxx00.#####.ppt 4/10/19 10:37:48 AMPediatric Cardiology Pediatric
Assessing Aneurysms
Page 24
xxx00.#####.ppt 4/10/19 10:37:49 AMPediatric Cardiology Pediatric
Giant Aneurysms and Prognosis
•Patients with giant aneurysms have worst prognosis
•30 year survival- 90%•Only 36% cardiac event free
(Tsuda et al AM Heart J 2014; 167: 249-58)(Manlhoit/PHN Pediatr Cardiol 2010)
Page 25
xxx00.#####.ppt 4/10/19 10:37:50 AMPediatric Cardiology Pediatric
•Summary:1. Echobrightness
2. Ectasia
3. Lack of distal tapering
4. Dilation
5. Aneurysm formation
6. Valve regurgitation
7. Aortic root involvement
8. Function9. Pericardial Effusion
Kawasaki Echo Read
Page 26
xxx00.#####.ppt 4/10/19 10:37:51 AMPediatric Cardiology Pediatric
•It is reasonable to obtain advanced imaging studies -computed tomographic angiography (CTA)-cardiac magnetic resonance imaging (CMRI)- invasive angiography
•Recommended on patients with:-severe proximal coronary artery abnormalities -when management decisions depend on visualization of distal segments -difficult to be seen by echocardiography
•Other vasculature can be imaged simultaneously
2017 Guidelines –Advanced Imaging in KD
Page 27
xxx00.#####.ppt 4/10/19 10:37:51 AMPediatric Cardiology Pediatric
•MR in KD-Demonstrates distal aneurysms
-Viability/delayed enhancement
-Myocardial perfusion
-See extracardiac dilation
-Frequently need anesthesia
•CT in KD-Better than MR for thrombus evaluation-Smaller slices than MRI-Down side: Radiation
Page 28
xxx00.#####.ppt 4/10/19 10:37:52 AMPediatric Cardiology Pediatric
Catheterization in KD
Page 29
xxx00.#####.ppt 4/10/19 10:37:53 AMPediatric Cardiology
Goal of Therapy •Decrease systemic inflammation
•Prevent coronary aneurysms
•Minimize peak dimensions of coronary aneursysm(s)
•Prevent coronary thrombosis
Page 30
xxx00.#####.ppt 4/10/19 10:37:54 AMPediatric Cardiology Pediatric
•2017 Guideline states- IVIG
•“Patients with complete and incomplete KD should be treated with high-dose IVIG (2 g/kg)”
-Aspirin:
•“Administration of moderate (30 – 50 mg/kg/day) to high dose (80 – 100 mg/kg/day) ASA is reasonable until the patient is afebrile, although there is no evidence that it reduces coronary artery aneurysms”
The Future of Initial KD Treatment
Page 31
xxx00.#####.ppt 4/10/19 10:37:54 AMPediatric Cardiology Pediatric
•What about steroids?-Traditionally has been a controversial topic
-But should we consider steroids as part of initial therapy?
The Future of Initial KD Treatment
Page 32
xxx00.#####.ppt 4/10/19 10:37:55 AMPediatric Cardiology Pediatric
•2017 Guideline states
-“Single-dose pulse methylprednisolone should not be administered with IVIG as routine primary therapy”
-“A longer course of corticosteroids (tapering over 2 – 3 weeks), together with IVIG and ASA may be considered for treatment of high-risk patients when such high risk can be identified in patients before initiation of treatment”
The Future of Initial KD Treatment
Page 33
xxx00.#####.ppt 4/10/19 10:37:56 AMPediatric Cardiology Pediatric
•2017 Guideline states…-“Approximately 10 – 20% of patients with KD develop recrudescent or persistent fever at least 36 hours after the end of their IVIG infusion and are termed IVIG resistant.”
When to Retreat?
Page 34
xxx00.#####.ppt 4/10/19 10:37:56 AMPediatric Cardiology Pediatric
IVIG resistance - Pathophysiology
Page 35
xxx00.#####.ppt 4/10/19 10:37:57 AMPediatric Cardiology Pediatric
2017 Guidelines - IVIG Resistance1. Second dose of IVIG (2 g/kg) after 36 hours
2. Methylprednisolone 20–30 mg/kg IV x 3 days, +/- taper of oral steroids
Second dose of IVIG (2 g/kg), IV steroids x 3 days, +/-taper of oral steroids
3. Second dose of IVIG (2 g/kg) with prolonged oral taper of prednisolone/prednisone
4. Infliximab (5 mg/kg) instead of 2nd IVIG or corticosteroidsBrian W. McCrindle et al. Circulation. 2017;135:e927-e999
OR
OR
OR
OR
Page 36
xxx00.#####.ppt 4/10/19 10:37:58 AMPediatric Cardiology Pediatric
5. Cyclosporine in those who have failed above
6. Highly refractory patients
- Anakinra
- Cyclophosphamide
- Plasma exchange
Brian W. McCrindle et al. Circulation. 2017;135:e927-e999
2017 Guidelines - IVIG Resistance
Page 37
xxx00.#####.ppt 4/10/19 10:37:58 AMPediatric Cardiology Pediatric
Problems with 2017 Guidelines
•No robust data from clinical trials for IVIG resistance
•No guidelines for sickest patients: children < 1 year of age, KD shock syndrome, severe CA abnormalities or macrophage activation syndrome
•Persistent disease (worsening labs, persistent to worsening symptoms) in the absence of fever
Page 38
xxx00.#####.ppt 4/10/19 10:37:59 AMPediatric Cardiology Pediatric
Children <1 Year of Age•These children are at greater risk of treatment failure and CA abnormalities
-Hispanics with worse outcomes
-61% male, 39% female
•Unpublished PHIS data (14,325 pts from 2004-2014): -<6 months – 5.9% (852)
-6 - 12 months – 11.1% (1,595)
•Delayed diagnosis due to paucity of signs - Incomplete KD
-May present in shock
Page 39
xxx00.#####.ppt 4/10/19 10:38:00 AMPediatric Cardiology Pediatric
•“Kawashocki”-Hypotension plus KD symptoms
- Incidence of ≈ 7%
•Compared to typical KD patients -Higher CRP, hyponatremia, hypoalbuminemia and thrombocytopenia
-↑IVIG resistance
-↑rates of CA abnormalities
- Increased risk of MR and prolonged myocardial dysfunction
Kawasaki Disease Shock Syndrome (KDSS)
Kanegaye JT, et al. Pediatrics. 2009;123:e783–e789.
Page 40
xxx00.#####.ppt 4/10/19 10:38:01 AMPediatric Cardiology
KDSS
2017 Guidelines
•Initial IVIG and ASA
•Guidelines hint that KDSS
are IVIG resistant
•If IVIG resistant proceed
with options 1,2, 3 or 4,
etc
TCH
Additional therapy driven by clinical
course
2nd dose of IVIG if IVIG resistant [2]
Initial IVIG and ASA w/ IV methylprednisolone 30 mg/kg x (3
pulses) w/ oral steroid taper
Page 41
xxx00.#####.ppt 4/10/19 10:38:02 AMPediatric Cardiology
KD with Severe CA Abnormalities 2017 Guidelines
•No guidelines
•Only case reports with limited outcomes
•Worrisome since these patients are at greatest risk of morbidity and mortality
TCH
IV methylprednisolone 30 mg/kg x (3 pulses) w/ oral steroid taper and infliximab vs other anakinra
+/- 2nd dose of IVIG [1] if IVIG resistant
Initial IVIG and ASA
Page 42
xxx00.#####.ppt 4/10/19 10:38:03 AMPediatric Cardiology
Persistent Features w/o Fever
2017 Guidelines
•No guidelines outside of initial therapy
TCH
Additional therapy driven by clinical course
IV methylprednisolone 30 mg/kg x (~3 pulses) w/ oral
corticosteroid taper [2]
Initial IVIG and ASA
Page 43
xxx00.#####.ppt 4/10/19 10:38:04 AMPediatric Cardiology Pediatric
•Most common in first 45 days
•Contributing factors:- thrombocytosis
- increased platelet adhesion
- inflammation
-endothelial dysfunction
-abnormal flow conditions
Thromboprophylaxis in KD
Page 44
xxx00.#####.ppt 4/10/19 10:38:05 AMPediatric Cardiology Pediatric
•Aspirin – low dose until coronary artery normalization
•Clopidogrel - increased risk of thrombosis or aspirin non-responder
•Lovenox - the anti-inflammatory actions and anticoagulant effects
Thromboprophylaxis in KD
Page 45
xxx00.#####.ppt 4/10/19 10:38:06 AMPediatric Cardiology Pediatric
2017 guidelines –KD Risk Evaluation
Page 46
xxx00.#####.ppt 4/10/19 10:38:07 AMPediatric Cardiology Pediatric
2017 Guidelines - Echo Surveillance
• Twice weekly while rapidly expanding
• First 45 days: weekly• First 3 months:
monthly• Every 3 months for
first year
Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease: A Scientific Statement from the AHA. 2013; Circulation
Page 47
xxx00.#####.ppt 4/10/19 10:38:07 AMPediatric Cardiology Pediatric
Kawasaki Disease Follow Up
Page 48
xxx00.#####.ppt 4/10/19 10:38:09 AMPediatric Cardiology Pediatric
Kawasaki Disease Follow Up
Page 49
xxx00.#####.ppt 4/10/19 10:38:10 AMPediatric Cardiology Pediatric
Kawasaki Disease Follow Up
Page 50
xxx00.#####.ppt 4/10/19 10:38:11 AMPediatric Cardiology Pediatric
Kawasaki Disease Follow Up
Page 51
xxx00.#####.ppt 4/10/19 10:38:13 AMPediatric Cardiology Pediatric
Kawasaki Disease Follow Up
Page 52
xxx00.#####.ppt 4/10/19 10:38:15 AMPediatric Cardiology Pediatric
•At TCH
- Infrequent follow-up throughout childhood
•Echocardiogram
•Electrocardiogram
•Clinic visit
•If sports – perfusion imaging (cMRI)
Kawasaki Disease Follow Up
Page 53
xxx00.#####.ppt 4/10/19 10:38:16 AMPediatric Cardiology Pediatric
Rheumatology Follow Up
•Children < 1 year or any child with a complicated KD course
•Follow up labs (i.e., CBC, LFTs, inflammatory markers, albumin, sodium) and clinical course
•Tapering of corticosteroids and other therapies if necessary, are based on improvement of labs and collaboration with cardiology
Page 54
xxx00.#####.ppt 4/10/19 10:38:17 AMPediatric Cardiology Pediatric
•Defer live virus vaccines for 11 months -MMR -Varicella-Flumist-Rotavirus-Zoster
-Smallpox
-Yellow fever
2017 Guidelines –Immunizations After IVIG in KD
Page 55
xxx00.#####.ppt 4/10/19 10:38:17 AMPediatric Cardiology Pediatric
Thank you